What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complete pathologic response has been shown to be an appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, Robert B., Hines, Jacobi B., Torri, Valter, Porcu, Luca, Donington, Jessica, Bestvina, Christine M., Vokes, Everett, Dolezal, James M., Esposito, Alessandra, Garassino, Marina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504845/
https://www.ncbi.nlm.nih.gov/pubmed/37720499
http://dx.doi.org/10.1177/17588359231198446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504845/
https://www.ncbi.nlm.nih.gov/pubmed/37720499
http://dx.doi.org/10.1177/17588359231198446

Ejemplares similares